Intra-Cellular Therapies (ITCI) to Release Earnings on Tuesday

Intra-Cellular Therapies (NASDAQ:ITCI) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, May 7th. Analysts expect Intra-Cellular Therapies to post earnings of ($0.31) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Intra-Cellular Therapies (NASDAQ:ITCI) last released its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.14. Intra-Cellular Therapies had a negative net margin of 30.08% and a negative return on equity of 23.02%. The business had revenue of $132.10 million for the quarter, compared to the consensus estimate of $135.97 million. During the same period in the prior year, the firm earned ($0.45) EPS. The business’s revenue for the quarter was up 50.3% on a year-over-year basis. On average, analysts expect Intra-Cellular Therapies to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Intra-Cellular Therapies Price Performance

Shares of Intra-Cellular Therapies stock opened at $68.80 on Friday. The firm has a fifty day moving average price of $69.16 and a 200 day moving average price of $65.46. Intra-Cellular Therapies has a 1 year low of $45.50 and a 1 year high of $84.89.

Analyst Ratings Changes

ITCI has been the subject of a number of recent research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $120.00 price objective on shares of Intra-Cellular Therapies in a report on Wednesday, April 24th. Needham & Company LLC lifted their target price on shares of Intra-Cellular Therapies from $82.00 to $90.00 and gave the company a “buy” rating in a report on Monday, April 22nd. Royal Bank of Canada reiterated an “outperform” rating and issued a $86.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 3rd. The Goldman Sachs Group raised their price target on shares of Intra-Cellular Therapies from $67.00 to $77.00 and gave the company a “neutral” rating in a research report on Wednesday, April 17th. Finally, Canaccord Genuity Group upped their price objective on shares of Intra-Cellular Therapies from $100.00 to $107.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $90.17.

Insider Buying and Selling

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 40,712 shares of the stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $66.50, for a total transaction of $2,707,348.00. Following the completion of the transaction, the chief executive officer now owns 1,050,309 shares of the company’s stock, valued at $69,845,548.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, CFO Lawrence J. Hineline sold 13,337 shares of the firm’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $69.43, for a total value of $925,987.91. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Sharon Mates sold 40,712 shares of the company’s stock in a transaction dated Thursday, March 7th. The shares were sold at an average price of $66.50, for a total transaction of $2,707,348.00. Following the sale, the chief executive officer now directly owns 1,050,309 shares of the company’s stock, valued at approximately $69,845,548.50. The disclosure for this sale can be found here. In the last three months, insiders have sold 168,487 shares of company stock worth $11,364,950. Insiders own 3.40% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.